SMFM Responds to the Published Results of the CHAP Trial

Washington, DC – The Society for Maternal-Fetal (SMFM) released the following statement in response to the published results of “Treatment for Mild Chronic Hypertension during Pregnancy,” in the New England Journal of Medicine.

“SMFM has supported the 2019 guidelines from the American College of Obstetricians and Gynecologists, which do not recommend pharmacologic treatment for mild chronic hypertension during pregnancy. Historically, this recommendation results from a lack of data confirming maternal or perinatal benefit with treatment and concerns that antihypertensive therapy may impair fetal growth.

The Chronic Hypertension and Pregnancy (CHAP) Trial provides new data regarding the benefits and safety of pharmacologic therapy for mild chronic hypertension in pregnancy. SMFM’s Publications Committee is currently reviewing the results of the trial and will issue revised clinical guidance, as appropriate.”